AMICAR ORAL SOLUTION Rx
Generic Name and Formulations:
Aminocaproic acid 250mg/mL; raspberry-flavor.
Indications for AMICAR ORAL SOLUTION:
Bleeding associated with fibrinolysis.
Initially 5g during 1st hour, then 1g/hour for 8 hours or until bleeding is controlled.
Active intravascular clotting process. Disseminated intravascular coagulation without concomitant heparin.
Upper urinary tract bleeding: not recommended. Cardiac, hepatic or renal disease. Risk of myopathy with long-term use; monitor creatine phosphokinase (CPK); discontinue if CPK rises. Avoid rapid IV administration. Neonates. Pregnancy (Cat.C). Nursing mothers.
Avoid concomitant Factor IX complex or Anti-inhibitor Coagulant concentrates; may increase thrombosis risk.
Inj site reactions, bradycardia, hypotension, GI upset, edema, headache, malaise, CNS effects, thrombosis, others; rare: myopathy.
Tabs—100; Oral soln—473mL; Inj—contact supplier
Endocrinology Advisor Articles
- Fasting Glycemic Variability Indicates Increased Risk for Type 2 Diabetes
- Heritability of BMI Stronger in Obesogenic Environments
- Adverse Events Associated With Diazoxide Treatment for Congenital Hyperinsulinism
- Maternal Gluten Intake Associated With Risk for Type 1 Diabetes in Offspring
- Domestic Refrigeration May Pose Underestimated Risk for Insulin Quality
- Vitamin D Supplementation Has No Effect on Musculoskeletal Health
- Deep Learning Algorithm Efficiently Detects Vision-Threatening Diabetic Retinopathy
- Industry-Funded Trials Often Involve Employees in Studies
- Nutrition Tips for Physicians: Staying Healthy During Busy Days
- Early-Onset Asthma/Wheezing Associated With Later Childhood Obesity